CNTY-813 is an iPSC-derived islet cell replacement therapy engineered with Allo-Evasion™ 5.0 for patients with type 1 diabetes; on track for IND submission in 4Q 2026 ...

Landmark Hamilton development advances one of Australia’s largest integrated energy, agriculture, and protein infrastructure projects. Landmark infrastructure requires scale, discipline, and long-term ...

Kriya’s integrated R&D and manufacturing platform is designed to make gene therapies accessible for more common chronic diseasesASGCT ...

Interim clinical results for the BB-301 Phase 1b/2a study include 12-month post-treatment follow-up results for the first four Cohort 1 ...

Management plans to file for regulatory approval of "Tresmi" for PAH and ILD this year, with commercial launch targeted for next year. Tyvaso DPI platform enhancement -- Introduction of 80-microgram ...

Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 ...

Kmind Strategy Consulting, an international leader in business competition methodology, presented its proprietary Strategic ...

Michael will discuss first quarter 2026 financial results and corporate highlights. Lindsey will then provide details on financial performance and overall outlook for the year. This will be followed ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Q1 2026 Earnings Call April 29, 2026 8:00 AM EDTCompany ParticipantsTom Barth - Head of Investor RelationsMichael Gianoni ...

Hyundai Motor and TVS Motor have signed a joint development agreement to co-develop electric three-wheelers for India, ...

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that ...